首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
【24h】

DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.

机译:用反式激活域中突变的HIV-1 tat进行的DNA免疫诱导了针对野生型Tat的体液和细胞免疫应答。

获取原文
获取原文并翻译 | 示例
           

摘要

Intramuscular immunization of mice with plasmids encoding two transdominant negative mutants of the HIV-1 Tat protein (Tat22 and Tat22/37) elicited a humoral response to wild-type Tat that is comparable to that induced by inoculation of wild-type tat DNA or Tat protein. The percentage of the responders and the Ab titers continued to increase after three additional DNA boosts and pretreatment with bupivacaine at the site of inoculation, without a significant difference (p > 0.05) among the three groups of mice immunized with mutant and wild-type tat genes. By utilizing synthetic peptides representing the amino acid sequence of Tat, one major B cell epitope was defined within the cysteine-rich domain of Tat. Anti-Tat IgG Abs directed against this epitope were found in mice immunized with all tat DNA constructs, whereas different Tat epitopes were detected in mice immunized with the Tat protein. Similarly, IgG2a was the predominant isotype in DNA-immunized mice, with both mutants and wild-type tat genes, as compared with protein immunization, which induced mostly IgG1 and IgG3. Sera from most immunized mice neutralized the effect of extracellular Tat in activating HIV-1 replication. A cellular response was also elicited as indicated by the proliferation of splenocytes when stimulated with wild-type Tat. These results indicate that the wild-type Tat Ag is recognized by Abs and T cells induced by DNA immunization with mutated tat genes, suggesting the possible use of these Tat transdominant mutants, lacking viral trans activation activity and capable of blocking wild-type Tat activity, in the development of an anti-HIV-1 vaccine.
机译:用编码两个HIV-1 Tat蛋白的显性负突变体(Tat22和Tat22 / 37)的质粒对小鼠进行肌肉内免疫,引起了对野生型Tat的体液反应,相当于通过接种野生型tat DNA或Tat诱导的体液反应蛋白。在接种部位再进行3次DNA增强和布比卡因预处理后,应答者和Ab滴度的百分比继续增加,在用突变和野生型tat免疫的三组小鼠中,无显着差异(p> 0.05)基因。通过利用代表Tat氨基酸序列的合成肽,在Tat富含半胱氨酸的结构域内定义了一个主要的B细胞表位。在用所有tat DNA构建物免疫的小鼠中发现了针对该表位的抗Tat IgG Abs,而在用Tat蛋白免疫的小鼠中检测到了不同的Tat表位。同样,与蛋白质免疫相比,IgG2a是DNA免疫小鼠的主要同种型,具有突变体和野生型tat基因,而蛋白质免疫主要诱导IgG1和IgG3。大多数免疫小鼠的血清中和了细胞外Tat激活HIV-1复制的作用。当用野生型Tat刺激时,脾细胞的增殖也表明引起细胞应答。这些结果表明野生型Tat Ag被突变的tat基因进行DNA免疫诱导的Abs和T细胞识别,表明可能使用这些Tat转化型突变体,缺乏病毒反式激活活性并能够阻断野生型Tat活性。开发抗HIV-1疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号